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Traditionally, the treatment of overactive bladder syndrome has been based on the use of 
oral medications with the purpose of reestablishing the detrusor stability. The recent better 
understanding of the urothelial physiology fostered conceptual changes, and the oral an-
ticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only 
recognized for their properties of inhibiting the detrusor contractile activity, but also their 
action on the bladder afference, and therefore, on the reduction of the symptoms that cons-
titute the syndrome. Beta-adrenergic agonists, which were recently added to the list of dru-
gs for the treatment of overactive bladder, still wait for a definitive positioning – as either a 
second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, 
whether due to unsatisfactory results or the presence of adverse side effects, define it as 
refractory overactive bladder. In this context, the intravesical injection of botulinum toxin 
type A emerged as an effective option for the existing gap between the primary measures 
and more complex procedures such as bladder augmentation. Sacral neuromodulation, 
described three decades ago, had its indication reinforced in this overactive bladder era. 
Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative 
to treat those with refractory overactive bladder. The results of the systematic literature 
review on the oral pharmacological treatment and the treatment of refractory overactive 
bladder gave rise to this second part of the review article Overactive Bladder – 18 years, 
prepared during the 1st Latin-American Consultation on Overactive Bladder.
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InTRODuCTIOn
This second part of the review article Ove-
ractive Bladder (OAB) – 18 years will address the 
oral pharmacological treatment and the treatment 
of refractory overactive bladder. A large number 
of studies on basic sciences gave rise to conceptual 
changes in the treatment of OAB. The urothelium 
– for decades viewed as a simple interface betwe-
en the detrusor muscle wall and the urinary con-
tent – took a critical position in the pathophysio-
logy and therapeutics of OAB. The identification 
of pharmacologic receptors, interconnected by a 
complex neurotransmitter network allowed for a 
better understanding of the role of neural affe-
rence in OAB. Oral anticholinergic agents, used by 
focusing on efference, started to be recognized for 
their parallel action on the modulation of bladder 
filling sensations. A new therapeutic option, still 
with a limited number of studies – beta-adrenergic 
agonists – were integrated to the armamentarium 
of oral medications. 
Electrical stimulation of the tibial ner-
ve strengthened the physiotherapeutic measures, 
now focusing on non-responsive cases to prima-
ry behavioral approaches and oral medications. 
Like oral anticholinergic agents, bolutinum toxin 
type A had its action initially based on the neu-
romuscular cholinergic blockage and consequent 
inhibition of the detrusor overactivity. Once again, 
recent advances on the urothelium physiology 
led to the recognition of a number of botulinum 
toxin actions on receptors that have a direct ac-
tion on the bladder afference. This stimulated the 
expansion its use from neurogenic cases to OAB 
patients with or without detrusor overactivity. In 
parallel, sacral neuromodulation had its indication 
strengthened for the treatment of refractory OAB, 
although still in a restricted manner in our com-
munity. 
Ninety-seven of 2,508 publications pre-
viously surveyed in the medical literature for the 
period from 1997 to 2014 were selected by two 
independent investigators, as described in the first 
part of this review. Table 1 outlines the keywords 
used and the details of the selection of articles. 
Only full texts in English, Spanish and Portuguese 
were included. Articles only containing abstracts 
or published in annals of congresses were exclu-
ded. In cases of similar publications, the most re-
cent one and showing the highest level of scien-
tific evidence was selected. 
The articles were reviewed and their re-
sults compiled during the 1st Latin-American 
Consultation on Overactive Bladder. The present 
text was prepared from the works presented in a 
plenary session of the event with the participa-
tion of all members of the Consultation.
Overactive bladder management with oral me-
dications
Antimuscarinic agents are for many years 
the first pharmacological treatment option for 
overactive bladder. Yet, many safety and tolera-
bility-related aspects limit their use (1-4). Special 
attention should be given to the interaction of 
antimuscarinic agents with other drugs common-
ly used by the elderly, prescribed by cardiologists, 
general practitioners, and psychiatrists. Many of 
these drugs either have anticholinergic effects or 
may interfere with the hepatic metabolism and 
thereby enhance the adverse effects of the anti-
muscarinic agents that are used in the treatment 
of overactive bladder. 
Five subtypes of muscarinic receptors are 
found in the human body, classified as M1, M2, 
M3, M4, and M5. The smooth detrusor muscle 
and the urothelium mainly contain M2 and M3 
receptors. In the urinary tract, while there is a 
higher proportion of M2 receptors, M3 receptors 
are responsible for bladder contraction. M2 and 
M3 receptors are also found in other human or-
gans, such as salivary glands and bowel, which 
may result in adverse reactions from treatments 
with antimuscarinic agents (4-7). 
Some pharmacokinetic characteristics of 
the antimuscarinic agents are important in the 
genesis of side effects, such as the ability to cross 
the blood-brain barrier determined by the mole-
cular weight and level of liposolubility or lipo-
philicity (2, 4, 7). In turn, the affinity (pKi) with 
each receptor also determines differences in the 
clinical effects. Antimuscarinic agents with lower 
affinity to M1 receptors (abundant in the central 
nervous system) provide low risks of neurologi-
cal adverse effects, even if they cross the blood-
-brain barrier. In contrast, those with affinity to 
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Table 1 - Method of search of scientific publication at pubMed, Bireme
Groupst Strategy of search Filters Total of 
identified 
articles
Total of 
selected 
articles
Concept and diagnosis of 
Overactive bladder
( "Urinary Bladder, Overactive/
classification"[Mesh] OR 
"Urinary Bladder, Overactive/
diagnosis"[Mesh] OR "Urinary 
Bladder, Overactive/etiology"[Mesh] 
OR "Urinary Bladder, Overactive/
pathology"[Mesh] OR 
"Urinary Bladder, Overactive/
physiopathology"[Mesh] ) OR 
( "Urinary Incontinence, Urge/
classification"[Mesh] OR  
"Urinary Incontinence, Urge/
diagnosis"[Mesh] OR  "Urinary 
Incontinence, Urge/etiology"[Mesh] 
OR  "Urinary Incontinence, 
Urge/pathology"[Mesh] OR  
"Urinary Incontinence, Urge/
physiopathology"[Mesh] )
English/spanish/portuguese 
+ abstract available + 
01/01/1985 a 31/05/2014 + 
humans + >19 years
799 53
Epidemiology (Urinary Incontinence, Urge or 
Urinary Bladder, Overactive) and 
(economics or epidemiology)
English/spanish/portuguese 
+ abstract available + 
01/01/1985 a 31/05/2014 + 
humans + >19 anos
713 51
Conservative
Non-Pharmacological 
Management
(Urinary Incontinence, Urge or 
Urinary Bladder, Overactive) and 
(diet therapy or drug therapy 
or prevention or control or 
rehabilitation or surgery or treatment 
or therapy)
English/spanish/portuguese 
+ abstract available + 
01/01/1985 a 31/05/2014 + 
humans + >19 anos
Clinical trials, Review, 
Randomized Clinical Trial
996
35
Pharmacological Management 71
Refractory
Overactive Bladder
26
M1 muscarinic receptors may trigger cognitive di-
sorders, memory loss, drowsiness, confusion, and 
even accelerate the emergence of dementias. The 
drug’s ability to interact with P glycoproteins, whi-
ch convey substrates into the nerve cell, also works 
as a determining factor of adverse effects. 
Another important characteristic is the drug 
exposure time, determined by the metabolism in 
the liver. It is well known that the elderly loses he-
patic mass and blood flow, which may reduce the 
drug elimination via cytochrome CYP3A4, there-
by prolonging the permanence of the drug in the 
blood stream (7).
Several antimuscarinic agents have been 
studied in the treatment of overactive bladder, in-
cluding oxybutynin, tolterodine, solifenacin, da-
rifenacin, trospium, fesoterodine and propiverine 
(4, 6, 8-11). These drugs mainly have their effects 
through the inhibition of muscarinic receptors pre-
sent in the bladder – in both the detrusor muscle 
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and the urothelium (10). In turn, they differ from 
each other in both their molecular structure and 
pharmacokinetic proprieties, which leads to diffe-
rences in their clinical effects (4, 7). The efficacy of 
the different antimuscarinic agents is very similar, 
with their main difference lying on their adverse 
effects. 
Several studies having an appropriate me-
thodologic design showed the efficacy of antimus-
carinic agents in controlling overactive bladder 
symptoms. However, adherence to treatment has 
been an issue, once discontinuation is reported in 
up to 80% of patients in a one-year follow-up (12). 
Because overactive bladder is a chronic condition 
and the long-term treatment with antimuscarinic 
agents is usually necessary, optimizing the tolera-
bility of the drug is critical in obtaining patient sa-
tisfaction. The extended-release (ER) formulations 
show lower adverse effect rates, probably because 
they provide more homogeneous plasma concen-
tration levels with lower peaks when compared to 
immediate-release formulations (13-15). 
There are several limiting factors when in-
terpreting and analyzing the results reported by the 
numerous clinical studies of anticholinergic agents 
for the treatment of overactive bladder. A relevant 
factor – reiterated in a number of these studies – is 
the high frequency of positive response to placebo – 
approximately 30%, which makes the interpretation 
of results more difficult. Another factor that stands 
out is the variability of the study populations in ter-
ms of severity of symptoms as well as the assess-
ment methods employed in the clinical trials.
Clinical efficacy of antimuscarinic agents in the 
treatment of overactive bladder 
An extensive review of clinical trials eva-
luating pharmacological therapies of overactive 
bladder did not reveal any evidence of clinical 
efficacy differences among the many studied 
pharmacological agents (16-81). This finding is 
consistent with the conclusions of many publi-
shed systematic reviews and meta-analysis (13, 
14, 82-93). 
From the studies published, a Cochrane 
review stands out. It demonstrated that solife-
nacin was superior to tolterodine in the domain 
of quality of life, according to information pro-
vided by patients about their daily urgency and 
incontinence symptoms. The tolerance to both 
drugs were similar. Solifenacin showed equivalent 
efficacy, but with higher tolerance and quality of 
life than darifenacin (88). The extended-release 
(ER) formulations provided higher improvement 
of quality of life than the immediate-release (IR) 
ones. When compared to tolterodine-IR, oxybuty-
nin-ER had a similar quality-of-life profile, while 
solifenacin showed superior efficacy and quality 
of life. In three trials, fesoterodine showed to be 
more effective, providing superior quality of life 
when compared to tolterodine-ER (89). 
In the SOLIDAR study, the authors compa-
red the selective antimuscarinic agents solifenacin 
(5 mg) and darifenacin (7.5 mg). Both showed to 
be equivalent in the results of reducing overac-
tive bladder symptoms; however, solifenacin was 
superior in quality of life and satisfaction, with a 
lower incidence of dry mouth (94). 
Applying oxybutynin through transdermal 
patches resulted in similar improvement to that 
achieved with the oral use of this agent, just with 
fewer adverse effects (33). Similar results were 
observed when transdermal oxybutynin and oral 
tolterodine ER were compared (34).
What are the adverse effects of antimuscarinic 
agents? 
Several meta-analyses were designed to 
evaluate the information provided by clinical 
trials, specifically regarding adverse effects, whi-
ch allows us to more easily visualize the safety 
level of each drug in the distinct presentations 
and routes of administration. 
Chapple et al. (83) conducted a systema-
tic review and meta-analysis of 83 clinical trials 
in which four formulations were associated with 
a high risk of discontinuation due to adverse 
events when compared to placebo – oxybutynin 
IR, 7.5-10 mg/d; oxybutynin IR, 15 mg/d; pro-
piverine ER, 20 mg/d; and solifenacin, 10 mg/d. 
Tolterodine ER 4 mg/d was the only formulation 
associated with low risk of discontinuation when 
compared to placebo. Reports of dry mouth of 
any severity were the most commonly seen with 
all the interventions, with significant difference 
when compared to placebo. The relative risk ran-
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ged from 2.1 to 5.9 and increased when the doses 
of darifenacin, fesoterodine, solifenacin, and tolte-
rodine were increased. This tendency was not evi-
dent for oxybutynin and propiverine. Other adver-
se effects were significantly high with the active 
treatment when compared to placebo, including: 
blurred vision, constipation, erythema, fatigue, 
pruritus, excessive sweating, and urinary retention. 
Another meta-analysis on adverse effects 
showed fewer patients with dry mouth when 
using ER formulations of oxybutynin and tolte-
rodine when compared to IR formulation of both 
drugs, with significant results. There were no wi-
thin-group differences for the different doses of 
each medication (82). 
Trospium chloride, darifenacin and fe-
soterodine are active substrates for the P glyco-
protein-dependent cell transport system, which 
means a high reduction of the blood-brain bar-
rier permeability, with low levels in the central 
nervous system; particularly trospium, which is 
almost undetectable in the cerebrospinal fluid 
and a good option in patients with risk of cogni-
tive worsening due to a number of neurological 
pathologies, such as Parkinson’s disease, multiple 
sclerosis, senile dementia, etc. (95, 96). 
A randomized, placebo-controlled, double-
-blind study compared the effects of oxybutynin 
topic gel, with oral IR oxybutynin and placebo on 
the cognitive and psychomotor functions in he-
althy elder patients (97). When compared to the 
oral IR formulation, oxybutynin gel has equiva-
lent efficiency, with reduced side effects and a cli-
nically significant effect of less worsening of the 
cognitive function in healthy older subjects. 
Recently, Kessler et al. (98) revealed gre-
at methodological and statistic creativity – which 
they compiled in a systematic review – by using a 
new meta-analysis referred to as “network meta-
-analysis.” Through this, after extracting the data 
from clinical trials, the adverse events were classi-
fied into seven categories (gastrointestinal, ocular/
visual, urinary tract-related, neurologic, cardiac, 
respiratory, and dermatological) of the Common 
Terminology Criteria for Adverse Events (CTCAE) 
and scored using the visual analogic scale (VAS): 
0=minimal severity and 10=maximum severity, 
based on a consensus of ten independent specia-
lists. This meta-analysis studied 60 trials invol-
ving 26,229 patients and found a similar global 
adverse effect profile for darifenacin, fesoterodine, 
transdermal oxybutynin, propiverine, solifenacin, 
tolterodine, and trospium, but not for oral oxybu-
tynin when compared to the initial dose. Oxybu-
tynin in doses equal or superior to 10 mg/dL had 
a worse adverse event profile. Darifenacin, fesote-
rodine, transdermal oxybutynin, propiverine, and 
solifenacin showed a significantly better dose-
-adverse effect correlation. Of all adverse effects, 
the gastrointestinal ones were the most frequently 
reported. Only the transdermal oxybutynin at 3.9 
mg/dL showed a gastrointestinal profile similar 
to placebo. Its visual/ocular adverse event profi-
le was similar among the antimuscarinic agents 
when the initial dose was used. The same was ob-
served for the urinary tract, neurologic, cardiac, 
and respiratory profiles. While the dermatological 
adverse effects were minor with the oral adminis-
tration of the drugs, the adverse event profile was 
worse with the transdermal administration. 
The absolute contraindications for the use 
of antimuscarinic agents include urinary reten-
tion, gastric retention, closed-angle glaucoma, 
and known hypersensitivity to the pharmacologi-
cal agent. The relative contraindications include 
partially obstructed bladder emptying, renal or 
hepatic changes, excessive use of alcohol, reduced 
gastrointestinal motility, constipation, and myas-
thenia Gravis (99).
What are the effects of beta-3-adrenergic agonists 
on overactive bladder symptoms and their adverse 
effects? 
Animal studies and clinical trials have sho-
wn that beta-3 agonists relax the detrusor muscle, 
thereby improving bladder filling and compliance. 
There is a significant improvement of the incon-
tinence and voiding episodes in 24 hours as well 
as a significant improvement of the quality of life 
(100, 101). 
The beta-3 agonist Mirabegron was ap-
proved for the treatment of overactive bladder 
in Japan in September 2011 and in Europe and 
the United States in June 2012 (102). Other beta-
3 agonists, such as Solabegron and TRK-380, are 
still under investigation (103, 104). 
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Experimental studies have demonstrated 
that beta-3 adrenergic receptor (β3AR) agonists 
result in relaxation of the smooth detrusor mus-
cle in humans mediated by the stimulation of the 
enzyme adenyl cyclase, which leads to the ac-
cumulation of cyclic adenosine monophosphate 
(AMPc). In addition, β3-AR activation seems to 
inhibit detrusor contraction also due to the relea-
se of urothelium-derived inhibitory factor (UDIF) 
(105, 106). 
Seven clinical studies showed that Mirabegron 
(25, 50, and 100 mg) results in a significant reduc-
tion of urinary incontinence and voiding episodes 
in 24 hours (107-111). Five of these studies used 
4-mg tolterodine ER as the active control group; 
five were phase III studies conducted to evaluate 
safety and efficacy, one was a phase II proof-of-
-concept study (111), and one was a phase II study 
of dose determination (109). One of the phase III 
studies included 1,978 patients from 27 European 
countries and Australia. All three active groups 
showed improvement when compared to placebo; 
however, tolterodine was only superior to placebo 
at week 4. The main limitation was the short pe-
riod of 12 weeks of treatment (110). 
Another international phase III randomi-
zed, placebo-controlled, double-blind, multicen-
ter clinical study conducted in the United States 
and Canada evaluated the effect of Mirabegron on 
overactive bladder patients experiencing symp-
toms for over three months. When compared to 
placebo, 50 mg and 100 mg Mirabegron resulted 
in a superior reduction of the number of inconti-
nence and voiding episodes in 24 hours (112). 
One study evaluated the urodynamic im-
pact of Mirabegron on bladder emptying in men. 
In this study, 200 men with lower urinary tract 
symptoms associated with benign prostatic hyper-
plasia were randomized to receive 50 mg or 100 
mg of Mirabegron or placebo daily during 12 we-
eks. There was no significant difference between 
groups, in terms of urinary flow and the detrusor 
pressure on the maximum flow (100). 
The pooled analysis of three phase III stu-
dies revealed that the global incidence of adver-
se events and serious adverse events was similar 
among the groups treated with Mirabegron, tolte-
rodine or placebo (15, 113). 
One study evaluated the potential of Mi-
rabegron to cause a change in the cardiac repola-
rization in healthy patients. The authors observed 
that Mirabegron did not prolong the QTc interval 
at the doses of 50 or 100 mg; only the 200 mg 
dose of Mirabegron caused an increase of the QTc 
interval superior to 10 ms in women (114). 
Mirabegron dose is recommended to be re-
duced in patients with renal and hepatic impair-
ment, and because it inhibits CYP enzyme, caution 
should be taken in patients using digoxin and me-
toprolol (101).
Treatment of refractory overactive bladder 
Patients that are refractory to conservati-
ve treatment, including behavioral, physiothera-
peutic and pharmacological treatments should be 
evaluated by a specialist, in case they want addi-
tional treatment. 
Patients considered refractory are those 
failing an adequate behavioral treatment, for long 
enough to evaluate the results, usually three mon-
ths, and that have also failed the pharmacological 
treatment with at least one antimuscarinic agent, 
taken for at least 4-8 weeks. Pharmacological tre-
atment failure may include lack of efficacy, drug 
intolerance, or absolute contraindication to its use. 
Treatment options after failure of conser-
vative treatment pose significant risks to patients. 
Therefore, before indicating such treatments, a 
thorough evaluation should take place in order to 
ensure that the complaints are truly resulting from 
idiopathic overactive bladder, rather than secon-
dary to other clinical conditions. 
The therapeutic options after conservative 
treatment failure include electrical stimulation of 
the tibial nerve, botulinum toxin injection into de-
trusor, and sacral neuromodulation (SNM). Each of 
these alternatives has advantages and disadvanta-
ges that will be addressed in the respective topic. 
The use of these therapeutic options re-
quires a careful selection of patients and detailed 
education. Such treatments may be offered in any 
order; that is, none of them could be considered as 
being superior to the others. If a patient fail in one 
of these treatments, he or she can be a candidate 
to another one. The efficacy of a combination of 
these therapeutic modalities is unknown.
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Electrical stimulation of the tibial nerve 
The peripheral electrical stimulation of 
the tibial nerve has been used in the treatment of 
bladder filling and urgency urinary incontinence 
symptoms. The impact of the treatment depends 
on the severity of the symptoms before treatment, 
the number of weekly sessions, and the evaluation 
time point following the procedure. This techni-
que can be performed transcutaneously or per-
cutaneously (115). The electrical stimulation has 
its effect by inhibiting the detrusor activity via 
afferent action of the pudendum nerve (116). In 
order to stimulate the tibial nerve percutaneous-
ly (PTNS), a 34G needle is inserted in a cephalic 
position in relation to the internal malleolus and 
for electrical stimulation, a low voltage (9V) with 
a width of 0-10mA is used, with a fixed frequency 
of 20Hz and pulse width of 200 ms. The majority 
of the studies evaluating this therapeutic modali-
ty is of case sequences, without a control group, 
and exclusively conducted in women. The equi-
pment, as well as the electrical stimulation para-
meters and weekly session protocols in these stu-
dies greatly varied. Most included relatively small 
samples (14-60 patients) with a short follow-up 
(12 weeks). In comparative studies of the use of 
PTNS with placebo, a reduction of more than 50% 
of the urgency and urge-incontinence symptoms 
in 54-71% of patients receiving against 0-22% 
of patients in the control group (117-119). Most 
studies showed improvement of quality of life as 
evaluated by different questionnaires (118-120). 
Systematic reviews demonstrated that 37-100% of 
patients treated with PTNS experienced treatment 
success, with different evaluation criteria having 
been adopted and minimum adverse effects (121-
123). A recent meta-analysis indicated a seven-
-fold higher chance of clinical improvement in the 
PTNS treated group versus control group. 
Studies evaluating the duration of PTNS 
effects without further treatments showed, after 
completion of the initial protocol, maintenance of 
efficacy for up to six months (124, 125). Studies 
with up to three-year follow-ups demonstrated 
sustained efficacy upon a monthly treatment, af-
ter one cycle for 12 weeks (117, 126). Maintenance 
protocols are variable and tend to be individuali-
zed. Typically, after the 12 weeks of initial treat-
ment, the interval between sessions is progressi-
vely increase until it reaches one session a month 
(118, 126). Patients experiencing recurrence with 
this maintenance protocol are adjusted and recei-
ve reapplications within shorter intervals. In the 
SUmiT study, 41% of patients required less than 
one session a month, 55% needed 1-2 monthly 
sessions, and 4% more than two sessions a month. 
The most commonly seen adverse effects of the 
treatment with PTNS include pain at the puncture 
site (medial malleolus), local bleeding, paresthesia, 
and excoriations. These effects are rare and affect 
about 5% of patients (118, 120). It is important to 
stress the high rate of abandon at the long term 
follow-up, which reaches as much as 42% (118).
Botulinum toxin
The botulinum toxin type A counting with 
the largest number of scientific studies and that is 
approved for the treatment of overactive bladder 
by the Food and Drug Administration (FDA) and 
European Medicines Agency (EMA) is the one called 
onabotulinumtoxinA. Other botulinum toxins, such 
as abobotulinumtoxinA and incobotulinumtoxinA, 
were less frequently studied for bladder indication. 
Their efficacy and safety are not well known. In 
addition, their use is not provided in label for this 
indication. For this reason, our text will be based 
on the data published on onabotulinumtoxinA. 
The treatment with onabotulinumtoxinA 
can be used to patients that are refractory to the 
conservative treatment, after detailed education. 
Patients must be able to attend frequent follow-up 
visits in order to evaluate the bladder emptying 
pattern. They must accept the possibility of inter-
mittent bladder catheterization, if necessary. 
The efficacy and side effects of the treat-
ment with onabotulinumtoxinA depend on the 
dose used. The recommended dose for most pa-
tients should be 100 or 150 U. The use of 150 U 
results in a discrete improvement of efficacy, but 
higher risk of urinary retention (127-130). 
Most studies evaluated the bolutinum to-
xin injection into the body of the bladder, sparing 
the bladder trigone (127-131). Different protocols 
were used, including injections into 10-20 bladder 
sites and dilution in such a way to inject 0.5-1.0 
mL per site. OnabotulinumtoxinA injection should 
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be performed deeply into the detrusor. Submuco-
sal injection was less often evaluated and its re-
sults are not well known. 
OnabotulinumtoxinA injection can be per-
formed with local anesthesia, sedation, spinal blo-
ck, or general anesthesia. The procedure with local 
anesthesia usually requires the use of flexible cys-
toscope and a longer injection needle, at a higher 
cost. With other forms of anesthesia, the procedu-
re can be performed with the aid of rigid cystosco-
pe and a shorter injection needle. This equipment 
is cheaper and easily available. The choice of the 
type of anesthesia should be agreed upon by both 
physician and patient, considering the equipment 
availability. 
OnabotulinumtoxinA at a dose of 100 or 
150 U results in improvement of several clinical 
parameters and the quality of life. The impact of 
the treatment on these parameters depends on the 
severity of symptoms before treatment, the dose 
used, and the evaluation time point after the pro-
cedure. In comparative studies of onabotulinu-
mtoxinA with placebo, a reduction of more than 
50% of urgency and urge-incontinence symptoms 
was observed in 57-68% of patients receiving 100 
U versus 27-30% of those receiving placebo. Total 
continence was observed in 23-55% of patients 
receiving 100 U versus 6-11% of those receiving 
placebo (129-131). The improvement of the qua-
lity of life, as evaluated through different ques-
tionnaires, was 60-63% among patients receiving 
100 U versus 27-29% of patients receiving place-
bo (130, 131). The urodynamic efficacy of the tre-
atment with onabotulinumtoxinA has been little 
studied. Some studies showed improvement of the 
cystometric bladder capacity (25%) and absence 
of the detrusor overactivity (35-39%) (132-134). 
The most commonly seen adverse effects 
following onabotulinumtoxinA injection include 
urinary tract infections, increase of the post-void 
residual volume, and urinary retention requiring 
bladder catheterization (127, 129-131). Urinary 
tract infections occurred in 15-55% of patients 
receiving 100 U versus 6-28% of those receiving 
placebo. Post-void residue superior to 150 mL was 
observed in 7-26% of patients receiving 100 U 
versus up to 1% of those receiving placebo (127-
131). Urinary retention requiring bladder cathete-
rization was observed in 3-18% of patients recei-
ving 100 U versus 0-2% of those receiving placebo 
(127-131, 134). The urinary retention may last a 
few days to several weeks, and in less than 50% 
of patients it lasts more than six weeks (128, 130). 
Other side effects include hematuria (4-18%) and 
muscular weakness (3-9%). 
The majority of studies evaluated patients 
during three months, and some studies evaluated 
patients for 6-12 months, with sustained efficacy 
throughout this period (127-131, 134, 135). 
Some factors are associated with a higher 
chance of complications, particularly urinary re-
tention requiring bladder catheterization. Among 
these factors, being male, over 75 years old, and 
initial post-void residue superior to 100 mL (132). 
Most of the studies evaluating reinjections 
are retrospective and without a control group. The 
interval between injections varied from 6 to 14 
months (136-139), with most of them showing 
maintenance of the treatment effects after reinjec-
tions (136, 137, 140). 
Treatment discontinuation is dependent on 
factors such as follow-up time, treatment efficacy 
and side effects, particularly urinary retention and 
urinary tract infections. In a study following up 
patients for 60 months, the treatment discontinua-
tion rate was 64% mainly due to the emergence of 
complications such as urinary retention and uri-
nary tract infections and for the lack of efficacy of 
the initial injection (138). 
The treatment with onabotulinumtoxinA 
may improve patients with moderate-to-severe 
symptoms of overactive bladder that did not res-
pond to the conservative treatment. The dose of 
100 U results in a lower rate of side effects. The 
benefits of the treatment with onabotulinumto-
xinA at a dose of 100 U outweigh the risks and 
discomforts in patients with refractory overactive 
bladder to the conservative treatment. It is critical 
that patients that are candidates for this treatment 
are carefully educated about the risks and they 
should accept the possibility that they need blad-
der catheterization for relief. Patients should also 
be informed that the effects of the treatment di-
minish over time and the vast majority will need 
reinjections. The current evidence limitations in-
clude short follow-up time in better designed stu-
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dies and variations of protocol injections and ad-
verse effect reporting.
Sacral neuromodulation 
Treatment with sacral neuromodulation 
(SNM) can be offered to patients with overactive 
bladder symptoms that are refractory to the conser-
vative treatment after detailed education. 
Studies evaluating this therapeutic modali-
ty are based on the use of the equipment Interstim 
(Medtronic, Minneapolis, USA), which has gone 
through changes in the last years, with the incorpo-
ration of a minimally invasive surgical technique, 
lower volume battery, anchored electrodes, and the 
introduction of the percutaneous stimulation tes-
ting (percutaneous nerve evaluation – PNE). 
The treatment with SNM involves a test 
phase (first phase), which may be performed with 
the implantation of a temporary electrode (PNE) or 
the implantation of the permanent electrode. The 
implantation of the electrode for PNE is simpler 
and less expensive; however, the results are inferior 
to those achieved with the permanent electrode. 
Studies reported as high success rates during the 
test phase with PNE as 44-60% (141-144) and 69-
81% with the implantation of the permanent elec-
trode (141, 142, 145, 146). Around 44% of patients 
failing the PNE test have positive response when 
undergoing a new test with the implantation of the 
permanent electrode (142). 
The second phase of the treatment is indica-
ted in cases showing good clinical response to the 
test phase. In general, a 50% or more improvement 
of urgency urinary incontinence symptoms is the 
parameter used as the success criterion. This tre-
atment phase consists of the implantation of the 
generator in cases where the permanent electrode 
was implanted during the test phase. In cases where 
the first phase was performed with PNE, the second 
phase consists of the implantation of the entire 
system, including the permanent electrode and the 
generator. 
Most of the studies evaluating this treat-
ment modality consist of observational series wi-
thout a control group. Some studies report long-
-term results (up to five years). Overall, studies 
show significant improvement of several clinical 
and quality-of-life parameters. 
Improvement of more than 50% of ur-
gency and incontinence symptoms is observed 
in 65-87% of patients in the short-term follow-
-up (up to six months) (147). Most of the patients 
have good results in the long run. Improvement 
of more than 50% of urgency and urgency in-
continence symptoms is observed in 62-70% of 
patients after a five-year follow-up (147-151). 
The satisfaction rates of patients followed up for 
more than five years is as high as 60-80% (152). 
The healing of urgency urinary incontinence is 
observed in 20-55% of patients (151, 153). 
Treatment results may be long-lasting, al-
though the adverse effect and additional surgery 
rates are significant. However, the potential varia-
bility of the rates observed in old studies as well as 
in more recent ones incorporating technological 
advances should be taken into account. The most 
commonly reported adverse effects include local 
pain at the generator implantation site (3-20%), 
pain at the electrode site (4-19%), electrode mi-
gration (1-9%), infection (2-14%), shock sensation 
(5-8%), and need for revision surgery (6-39%). In 
most studies, the revision surgery rates were su-
perior to 30%. There is evidence that the current 
procedures, with less invasive surgical technique 
and the use of anchored electrodes, result in lower 
adverse effect rates (147-151, 154, 155). In a stu-
dy evaluating patients from Medicare undergoing 
treatment with SNM in the period from 1997 to 
2007, the generator removal rate was about 11% 
in a 60-month follow-up on average (156). 
Patients should be informed about the 
need for periodic replacement of the generator, 
with the interval depending on the stimulation 
parameters used. Patients should be able to han-
dle the remote control in order to optimize the 
device functioning. Patients must accept the fact 
that magnetic resonance imaging is contraindi-
cated for individuals using the device (except for 
cranial magnetic resonance imaging, provided 
that the manufacturer’s instructions are follo-
wed). By taking into consideration the negative 
effects of the overactive bladder symptoms on 
patients’ quality of life, it is possible to state that 
the benefits from SNM outweigh the risks and 
discomforts of the treatment in selected, care-
fully educated patients. 
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Recommendation of this treatment is limi-
ted due to the fact that the majority of studies 
have an observational design, small samples, di-
fferent studies reporting results in the same group 
of patients, and the lack of information on the 
protocols used by patients in order to maintain the 
treatment results in the long term.
Surgical treatment of overactive bladder 
In rare occasions, bladder augmentation or 
urinary diversion may be considered in highly se-
lected patients with refractory overactive bladder. 
Almost all papers reporting results from bladder 
augmentation are based on populations with neu-
rogenic bladder dysfunctions. Very little is known 
about its use in patients with idiopathic overactive 
bladder. The risks of the procedure are high and 
many patients may need intermittent catheteriza-
tion for bladder emptying.
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